Glycosphingolipids in congenital disorders of glycosylation (CDG)

Mol Genet Metab. 2024 Mar 5;142(1):108434. doi: 10.1016/j.ymgme.2024.108434. Online ahead of print.

Abstract

Congenital disorders of glycosylation (CDG) are a large family of rare disorders affecting the different glycosylation pathways. Defective glycosylation can affect any organ, with varying symptoms among the different CDG. Even between individuals with the same CDG there is quite variable severity. Associating specific symptoms to deficiencies of certain glycoproteins or glycolipids is thus a challenging task. In this review, we focus on the glycosphingolipid (GSL) synthesis pathway, which is still rather unexplored in the context of CDG, and outline the functions of the main GSLs, including gangliosides, and their role in the central nervous system. We provide an overview of GSL studies that have been performed in CDG and show that abnormal GSL levels are not only observed in CDG directly affecting GSL synthesis, but also in better known CDG, such as PMM2-CDG. We highlight the importance of studying GSLs in CDG in order to better understand the pathophysiology of these disorders.

Keywords: CDG; Congenital disorders of glycosylation; GSLs; Gangliosides; Glycosphingolipids.

Publication types

  • Review